Progress of treatment for primary mediastinal B-cell lymphoma

Abstract

Abstract:Primary mediastinal B-cell lymphoma (PMBCL) is aggressive Bcell lymphoma with unique clinicopathologic characteristics. However, under the new classification of PMBCL, whether R-CHOP was the standard first-line immunotherapy regimen remains a controversy. The DA-EPOCH-R is not inferior to R-CHOP, but attention should be paid to the toxic effects. PMBCL is a radiosensitive disease, but radiotherapy did not as the front-line therapy for PMBCL. A biopsy is required for positive PET/CT after immunotherapy-chemotherapy to determine the further treatment of PMBCL. Recurrent/refractory PMBCL, with poor prognosis, salvage immunochemotherapy is often used followed by high-dose chemotherapy and autologous stem cell transplant. PD-1 overexpression is common in recurrent/refractory PMBCL, and immune checkpoint inhibitors are potential to be an important treatment option. Recently, the development of molecular medicine has provided a new basis for the selection of targets in PMBCL, however, it needs to be further confirmed by clinical trials.

Key words:Lymphoma, B-cell,Radiotherapy,Rituximab,Chemotherapy

Xiang Mingyue, Wang Lili, Han Dali. Progress of treatment for primary mediastinal B-cell lymphoma[J]. Journal of International Oncology, 2019, 46(8): 505-508.

References

［1］ Ceriani L, Milan L, Johnson PWM, et al. Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume［J］. Eur J Nucl Med Mol Imaging, 2019, 46(6): 1334-1344. DOI: 10.1007/s00259-019-04286-8. ［2］ Lees C, Keane C, Gandhi MK, et al. Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions［J］. Br J Haematol, 2019, 185(1): 25-41. DOI: 10.1111/bjh.15778. ［3］ Shah NN, Szabo A, Huntington SF, et al. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis［J］. Br J Haematol, 2018, 180(4): 534-544. DOI: 10.1111/bjh.15051. ［4］ Martelli M, Ferreri A, Di Rocco A, et al. Primary mediastinal large B-cell lymphoma［J］. Criti Rev Oncol Hematol, 2017, 113: 318-327. DOI: 10.1016/j.critrevonc.2017.01.009. ［5］ Lisenko K, Dingeldein G, Cremer M, et al. Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma［J］. BMC Cancer, 2017, 17(1): 359. DOI: 10.1186/s12885-017-3332-3. ［6］ Gleeson M, Hawkes EA, Cunningham D, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial［J］. Br J Haematol, 2016, 175(4): 668-672. DOI: 10.1111/bjh.14287. ［7］ Shah NN, Fenske TS, Hamadani M, et al. What is the standard of care for primary mediastinal B cell lymphoma; R-CHOP or DA-EPOCH-R? - Response to Melani et al［J］. Br J Haematol, 2019, 184(5): 838-840. DOI: 10.1111/bjh.15183. ［8］ GiulinoRoth L, O'Donohue T, Chen Z, et al. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R［J］. Br J Haematol, 2017, 179(5): 739-747. DOI: 10.1111/bjh.14951. ［9］ Wilson WH, sinHo J, Pitcher BN, et al. Phase Ⅲ randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma: CALGB/Alliance 50303［J］. Blood, 2016, 128(22): 469. ［10］ GiulinoRoth L. How I treat primary mediastinal B-cell lymphoma［J］. Blood, 2018, 132(8): 782-790. DOI: 10.1182/blood-2018-04-791566. ［11］ Jackson MW, Rusthoven CG, Jones BL, et al. Improved survival with combined modality therapy in the modern era for primary mediastinal B-cell lymphoma［J］. Am J Hematol, 2016, 91(5): 476-480. DOI: 10.1002/ajh.24325. ［12］ Melani C, Advani R, Roschewski M, et al. End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making［J］. Haematologica, 2018, 103(8): 1337-1344. DOI: 10.3324/haematol.2018.192492. ［13］ Messmer M, Tsai HL, Varadhan R, et al. R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma［J］. Leuk Lymphoma, 2019, 60(5): 1261-1265. DOI: 10.1080/10428194.2018.1519812. ［14］ Giri S, Bhatt VR, Pathak R, et al. Role of radiation therapy in primary mediastinal large B-cell lymphoma in rituximab era: a US population-based analysis［J］. Am J Hematol, 2015, 90(11): 1052-1054. DOI: 10.1002/ajh.24172. ［15］ De Sanctis V, Alfò M, Di Rocco A, et al. Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: results from a monoinstitutional cohort analysis of long-term survivors［J］. Hematol Oncol, 2017, 35(4): 554-560. DOI: 10.1002/hon.2377. ［16］ Bhatt VR, Mourya R, Shrestha R, et al. Primary mediastinal large B-cell lymphoma［J］. Cancer Treat Rev, 2015, 41(6): 476-485. DOI: 10.1016/j.ctrv.2015.04.006. ［17］ Ceriani L, Barrington S, Biggi A, et al. Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study［J］. Hematol Oncol, 2017, 35(4): 548-553. DOI: 10.1002/hon.2339. ［18］ Aoki T, Shimada K, Suzuki R, et al. Highdose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma［J］. Blood Cancer J, 2015, 5: e372. DOI: 10.1038/bcj.2015.101. ［19］ Avivi I, Boumendil A, Finel H, et al. Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation［J］. Bone Marrow Transplant, 2018, 53(8): 1001-1009. DOI: 10.1038/s41409-017-0063-7. ［20］ Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12［J］. J Clin Oncol, 2014, 32(31): 3490-3496. DOI: 10.1200/jco.2013.53.9593. ［21］ Kuruvilla J, Pintilie M, Tsang R, et al. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma［J］. Leuk Lymphoma, 2008, 49(7): 1329-1336. DOI: 10.1080/10428190802108870. ［22］ Mottok A, Wright G, Rosenwald A, et al. Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens［J］. Blood, 2018, 132(22): 2401-2405. DOI: 10.1182/blood-2018-05-851154. ［23］ Zinzani PL, Ribrag V, Moskowitz CH, et al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma［J］. Blood, 2017, 130(3): 267-270. DOI: 10.1182/blood-2016-12-758383. ［24］ Zinzani PL, Thieblemont C, Melnichenko V, et al. Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE-170 phase 2 trial［J］. Hematol Oncol, 2017, 35(S2): 62-63. DOI: 10.1002/hon.2437_49. ［25］ Yassin R, Hajeer A, Alshieban S, et al. HLA genotype and response to nivolumab therapy in relapsed refractory primary mediastinal B-cell lymphoma［J］. Curr Res Transl Med, 2019, 67(1): 31-33. DOI: 10.1016/j.retram.2018.11.001. ［26］ Sauter CS, Matasar MJ, Schoder H, et al. A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL［J］. Blood, 2018, 131(16): 1805-1808. DOI: 10.1182/blood-2017-08-802561. ［27］ Svoboda J, Landsburg DJ, Dwivedy Nasta S, et al. Brentuximab vedotin with R-CHP chemotherapy as frontline treatment for patients with CD30 positive primary mediastinal large B-cell, diffuse large B-cell, and grey zone lymphomas: results of a phase Ⅰ/Ⅱ multisite trial［J］. 2017, 130(Suppl 1): 191. ［28］ Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma［J］. N Engl J Med, 2017, 377(26): 2531-2544. DOI: 10.1056/NEJMoa1707447.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Qian Xiaotao, Shi Ziyi, Hu Ge.A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(3): 151-156.
[5]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing.Progress of radiotherapy in oligometastatic non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 170-174.
[6]	Jiang Xi, Wu Yongcun, Liang Yan, Chu Li, Duan Yingxin, Wang Lijun, Huo Junjie.Impact of pembrolizumab combined with chemotherapy on angiogenesis and circulating endothelial cells in patients with advanced non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(2): 89-94.
[7]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei.Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients[J]. Journal of International Oncology, 2024, 51(1): 37-42.
[8]	Cui Tenglu, Lyu lu, Sun Pengfei.Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma[J]. Journal of International Oncology, 2023, 50(9): 548-552.
[9]	An Rong, Liu Meihua, Wang Peichen, Wang Xiaohui.Research progress of Nrf2 in ovarian cancer[J]. Journal of International Oncology, 2023, 50(8): 493-497.
[10]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[11]	Lyu Lu, Sun Pengfei.Gut flora and cervical cancer[J]. Journal of International Oncology, 2023, 50(6): 373-376.
[12]	Radiation Oncology Treatment Physician Branch, Chinese Medical Doctor Association, Radiation Oncology Therapy Branch, Chinese Medical Association, Chinese Association of Radiation Therapy, China Anti-Cancer Association.Chinese experts' consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy （2023 version）[J]. Journal of International Oncology, 2023, 50(4): 193-201.
[13]	Xu Meng, Jiang Wei, Zhu Haitao, Cao Xiongfeng.Research progress of cancer-associated fibroblasts in tumor radiotherapy resistance[J]. Journal of International Oncology, 2023, 50(4): 227-230.
[14]	Shi Xaioqi, Wang Hongyan.Research progress on the interaction between gut microbiota and radiation enteritis[J]. Journal of International Oncology, 2023, 50(4): 244-247.
[15]	Zhao Yongrui, Gao Ying, Chen Yidong, Xu Jiankun.Efficacy and safety of linear accelerator-based fractionated stereotactic radiotherapy for small volume brain metastases[J]. Journal of International Oncology, 2023, 50(3): 138-143.